Skip to main content
x

OUR PASSION FOR PROGRESS BEGINS WITH OUR PIPELINE

For more than a decade, Neurelis has been working diligently to develop a pipeline of products and technologies to address significant unmet needs for patients.

NEURELIS PIPELINE

pipeline graphic
polygonPRE-CLIN
 
dotted circle

NRL-2
NRL-3

Phase 1PHASE
1
 
dotted circle

OPNT002

Phase 2PHASE
2
 
dotted circle

ARS-1
OPNT003
DP1038

Phase 3PHASE
3
 
dotted circle

 

NDANDA
 
dotted circle

NRL-1

FDAFDA
APPROVED
 
dotted circle

TOSYMRA™
(sumatriptan nasal spray)

NEURELIS PROGRAMS

NEURELIS PROGRAMS
DESCRIPTION
DISEASE STATE
STATUS
 
NRL-1
Intranasal Diazepam
Epilepsy
polygonNDA
Details
  • NDA filed
  • Orphan Drug designation
  • Fast Track
LEARN MORE ABOUT NRL-1 >
NRL-2
Intranasal Benzodiazepine
Anxiety
polygonPre-Clin
NRL-3
Intranasal Benzodiazepine
Epilepsy
polygonPre-Clin

Select Partner Programs

Select PARTNER PROGRAMS
DESCRIPTION
DISEASE STATE
STATUS
DETAILS
TOSYMRA™
(sumatriptan nasal spray)
Sumatriptan Nasal Spray
Acute Migraines
polygonFDA Approved
  • Upsher-Smith
  • Approved - Jan 2019
 
Tosymra is a trademark of Upsher-Smith Laboratories, LLC. Click here for full prescribing and important safety information.
ARS-1
Epinephrine Nasal Spray
Anaphylaxis
polygonPhase 2
  • ARS Pharmaceuticals
  • Fast Track designation
OPNT003
Nalmefene Nasal Spray
Opioid Overdose
polygonPhase 2
  • Opiant Pharmaceuticals
OPNT002
Opioid Antagonist Nasal Spray
Alcohol Use Disorder
polygonPhase 1
  • Opiant Pharmaceuticals
DP1038
Intranasal Octreotide
Acromegaly,
Neuroendocrine Tumors,
CID
polygonPhase 2
  • Dauntless
    Pharmaceuticals

Learn more about the innovative products in the Neurelis pipeline

NRL-1
NRL-2
NRL-3

THE NEURELIS TEAM HAS A ROBUST HISTORY OF CNS INDUSTRY EXPERIENCE

SEE OUR TECHNOLOGIES
PARTNER WITH US